Fairvalue-Calculator Fairvalue-Calculator
EN DE

Zhejiang Haisen Pharmaceutical Co (001367) Fair Value & Analysis

Healthcare · CN · Market cap 3.1B CNY

Price¥20.04
Fair Value¥19.00
Upside-5.2%
Quality95/100
Evidence: High Range ¥12.31 – ¥24.53

Fair value as of: Jun 25, 2026

Analysis

Zhejiang Haisen Pharmaceutical Co (001367) currently trades at ¥20.04, while our model-based Fair Value estimate is ¥19.00 — implying the stock looks roughly 5.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities. Zhejiang Haisen Pharmaceutical Co., Ltd. was incorporated in 1998 and is headquartered in Dongyang, China.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -60% Johnson & Johnson, (JNJ) -32% AbbVie Inc (ABBV) -52% Roche Holding (ROGN) -20% Merck & Co (MRCK34) -82% AstraZeneca PLC (A1ZN34) -85%

Frequently asked questions

Is Zhejiang Haisen Pharmaceutical Co (001367) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥19.00 versus a price of ¥20.04 — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 001367?
Our 21-model fair value for Zhejiang Haisen Pharmaceutical Co is ¥19.00 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥20.04.
What is the quality score of 001367?
Zhejiang Haisen Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.